FDA approves a Scancell Holdings IND to begin a registrational Phase 3 trial of iSCIB1+ in patients with advanced melanoma.
FDA cites Pine Pharmaceuticals for multiple quality and sterility violations following a 10-day inspection of the companys drug outsourcing facility i...
A Health Affairs analysis on FDAs new pathway allowing drug approvals based on a plausible mechanism of action warns that the approach raises unresolv...
Sarepta Therapeutics announces that its gene therapy Elevidys significantly slowed disease progression over three years in ambulatory patients with Du...
AMT-130 is a gene therapy designed to lower levels of the mutant huntingtin protein believed to drive Huntingtons disease progression.
U.S., U.K. and Canadian drug regulators announce a joint international symposium to discuss evolving regulatory expectations for clinical trials, bioe...
A federal judge sentences former CytoDyn chief executive Nader Pourhassan to 30 months in prison for misleading investors about the development of an ...
Advocacy groups urge Congress to advance legislation that would eliminate the statutory distinction between biosimilars and so-called interchangeable ...
